Antares Pharma to Present at the Jefferies 2018 Global Healthcare Conference
November 08 2018 - 7:00AM
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F.
Apple, President and Chief Executive Officer, will present at the
Jefferies 2018 Global Healthcare Conference on Thursday November
15, 2018 at 8:40 am (GMT) / 3:40 am (EST) in London, UK.
A live webcast of the presentation will be
available under the “For Investors” section of the Antares website,
www.antarespharma.com.
About Antares Pharma
Antares Pharma, Inc. is a specialty
pharmaceutical company focused on the development and
commercialization of self-administered parenteral pharmaceutical
products using advanced drug delivery auto injector
technology. The Company has a portfolio of proprietary and
partnered commercial products with several product candidates in
advanced stages of development, as well as significant strategic
alliances with industry leading pharmaceutical companies including
Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals,
Inc. and Pfizer Inc. (Pfizer). Antares Pharma’s proprietary
products include XYOSTED™ (testosterone enanthate) injection,
OTREXUP® (methotrexate) injection for subcutaneous use and
Sumatriptan Injection USP, which is distributed by Teva.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are subject to certain risks
and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such
differences include, but are not limited to: market acceptance,
adequate reimbursement coverage and commercial success of XYOSTED™
and future revenue from the same; market acceptance, adequate
reimbursement coverage and commercial success of Teva’s generic
epinephrine auto-injector product and future revenue from the same;
future market acceptance and revenue from AMAG’s Makena®
subcutaneous auto injector; Teva’s ability to successfully
commercialize VIBEX® Sumatriptan Injection USP and the amount of
revenue from the same; continued growth of prescriptions and sales
of OTREXUP®; successful completion of the asset sale transaction
with Ferring International Center, S.A.; the timing and results of
the Company’s or its partners’ research projects or clinical trials
of product candidates in development including projects with Teva
and Pfizer; actions by the FDA or other regulatory agencies with
respect to the Company’s products or product candidates of its
partners; continued growth in product, development, licensing and
royalty revenue; the Company’s ability to obtain financial and
other resources for its research, development, clinical, and
commercial activities and other statements regarding matters that
are not historical facts, and involve predictions. These statements
involve known and unknown risks, uncertainties and other factors
that may cause actual results, performance, achievements or
prospects to be materially different from any future results,
performance, achievements or prospects expressed in or implied by
such forward-looking statements. In some cases you can identify
forward-looking statements by terminology such as ''may'',
''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'',
''anticipate'', ''believe'', ''estimate'', ''predict'',
''potential'', ''seem'', ''seek'', ''future'', ''continue'', or
''appear'' or the negative of these terms or similar expressions,
although not all forward-looking statements contain these
identifying words. Additional information concerning these and
other factors that may cause actual results to differ materially
from those anticipated in the forward-looking statements is
contained in the "Risk Factors" section of the Company's Annual
Report on Form 10-K, and in the Company's other periodic reports
and filings with the Securities and Exchange Commission. The
Company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release. All
forward-looking statements are based on information currently
available to the Company on the date hereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of
this press release, except as required by law.
Contact:Jack HowarthVice President, Corporate
Affairs609-359-3016jhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Apr 2023 to Apr 2024